Prometheus: A Platform for Rapid Development of Human Antibody-based Therapeutics and Prophylactics against Emerging Viral Threats

普罗米修斯CETR的总体目标是发现和开发基于人类抗体的预防和治疗方法，以预防和治疗两大类引起严重人畜共患疾病的A类优先病毒：克里米亚-刚果出血热病毒（CCHFV）、汉坦病毒安第斯病毒（ANDV）、Sin Nombre病毒（SNV）和普努拉病毒（PUUV）。CCHFV、ANDV和SNV是对国家安全和公众健康构成最高风险的A类病原体。在最近的年度审查中，世界卫生组织将CCHF指定为蓝图重点疾病，具有最大可能引起突发公共卫生事件。目前还没有针对这些药物的批准疫苗或治疗方法。普罗米修斯ctr是由来自学术界、政府和工业界的七个合作伙伴组成的一个相互交织的合作项目，分为两个项目和三个核心，将实现两个大目标，每个目标都旨在提供针对目标病毒病原体的治疗产品。我们将开发和交付：(1)针对CCHFV具有广泛疗效的基于抗体的治疗药物；(2)针对汉坦病毒ANDV和SNV具有广泛疗效的基于抗体的治疗药物。

The overarching goal of the Prometheus CETR is to discover and develop human antibody-based prophylactics and therapeutics against two major groups of Category A priority viruses that cause severe zoonotic disease—the nairovirus Crimean-Congo hemorrhagic fever virus (CCHFV), and the hantaviruses Andes virus (ANDV), Sin Nombre virus (SNV), and Puumula virus (PUUV). CCHFV, ANDV, and SNV are Category A agents that pose the highest risk to national security and public health. In their latest annual review, the World Health Organization designated CCHF as a Blueprint Priority Disease with the greatest potential to cause a public health emergency. There are no approved vaccines or treatments for any of these agents. The Prometheus CETR, an interwoven collaboration among seven partners from academia, government, and industry organized into two projects and three cores, will accomplish two Grand Goals that are each aimed at delivering a therapeutic product against our target viral pathogens. We will develop and deliver: (1) an antibody-based therapeutic with broad efficacy against CCHFV; and (2) an antibody-based therapeutic with broad efficacy against the hantaviruses ANDV and SNV.